BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sorin Group S.p.A. (SRN) Buys California Medical Laboratories (CalMed) for $14 Million


7/2/2012 8:28:11 AM

MILAN, Jul 02, 2012 (BUSINESS WIRE) -- Sorin Group (mil:SRN)(reuters code:SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the acquisition of California Medical Laboratories, Inc. ("CalMed"), a manufacturer of high quality cardiovascular cannulae, for $14 million.

CalMed develops, manufactures and distributes a complete range of cannulae, catheters and accessories for cardiac surgery. Available in more than 45 countries worldwide, CalMed products are approved by the US Food and Drug Administration (FDA) and are CE marked for commercialization in the European Union. In 2011 Fiscal Year (ended September 30th, 2011) CalMed reported revenues of almost $8 million.

This acquisition represents an ideal complement to Sorin existing cannulae offering and to the recent acquisition of the Estech minimally invasive cannulae product line.

"This deal confirms Sorin Group's commitment to further strengthen our presence in the cannulae segment and consolidate our relationship with cardiac surgeons and clinical perfusionists worldwide," said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.

"We believe that building on CalMed's rich product offering and pipeline and leveraging on Sorin's global sales network will drive to a significant adoption of these products by cardiac surgeons worldwide," said Mehmet Bicakci, President and CEO of CalMed.

Sorin will continue to develop innovative new products and make selective, strategic acquisitions to enhance its worldwide leadership position in the cardiopulmonary business. Today, more than half of worldwide cardiac surgery procedures are performed using Sorin cardiopulmonary products.

About Sorin Group

Sorin Group ( www.sorin.com ), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

About CalMed California Medical Laboratories, Inc., ( www.calmedlab.com ), based in Costa Mesa, California, develops, manufactures and distributes a complete range of cannulae, catheters and accessories for cardiac surgery. CalMed products are FDA cleared and CE marked and sold in more than 45 countries worldwide. For more information, please visit: www.sorin.com

SOURCE: SORIN GROUP

Martine Konorski

Director, Corporate Communications

Sorin Group

Tel: +33 (0)1 46 01 33 78

Mobile: +33 (0)6 76 12 67 73

e-mail: martine.konorski@sorin.com

or

Francesca Rambaudi

Director, Investor Relations

Sorin Group

Tel: +39 02 69969716

e-mail: investor.relations@sorin.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES